Generic versions of semaglutide, widely known by the brand name Ozempic, are beginning to appear in Canadian pharmacies after Health Canada approved products from Dr. Reddy’s Laboratories and Apotex Inc. According to CBC News, the approvals came after Novo Nordisk’s regulatory exclusivity for Ozempic ended in January, opening the door for generic competition in Canada.
Semaglutide is a GLP 1 medication used in the treatment of Type 2 diabetes and obesity. Dr. Reddy’s told CBC News that its generic version launched in Canada last week and is already available in select pharmacies for patients with a valid prescription, with broader national distribution expected soon. Apotex has also received approval, making Canada one of the first major markets to see generic versions of the drug reach consumers.
Experts say the arrival of generics could be a major turning point for patients, especially as the original brand name medication can cost roughly $300 to $400 per month. Mina Tadrous, an associate professor at the University of Toronto who studies drug policy, told CBC News that the first generic version of a medication is often priced at about 75 to 85 per cent of the brand name cost. If three or more versions enter the market, prices could eventually fall to around 35 per cent of the original price.
Brian Rodrigues, a professor in the faculty of pharmaceutical sciences at the University of British Columbia, told CBC News that generic semaglutide should work the same way in the body because it contains the same active ingredient. He said patients can expect the same intended effects, along with the same common side effects, including nausea, vomiting, diarrhea and constipation. Rare but more serious risks, such as pancreatitis, bowel obstruction or gallstone attacks, would also remain the same.
While the active ingredient is the same, the manufacturing process can differ. Rodrigues explained that Novo Nordisk’s Ozempic is produced through a complex process involving biological and chemical steps, while newer generic versions may be made using a more streamlined chemical process. Even so, the final molecule must meet Health Canada’s requirements for safety, effectiveness and quality before approval.
Health Canada told CBC News that it authorized the generic drugs after reviewing evidence submitted by the companies. The regulator said manufacturers must show that any differences in production do not affect the final medication. Tadrous added that Health Canada reviews manufacturing practices and may conduct site visits to ensure standards are being met.
The generics will also rely on international manufacturing networks. Dr. Reddy’s has facilities in India, the United Kingdom and Mexico. Apotex, although Canadian, told CBC News that its semaglutide injectors require a sterile injectable facility and will be manufactured in India through one of its partners. Tadrous said this is common because much of Canada’s drug supply is connected to global manufacturing chains.
The arrival of generic semaglutide could make the medication more accessible to Canadians who previously struggled with the high monthly cost. Experts say broader access could have major health implications, particularly for people managing obesity, diabetes and related conditions. Health Canada is also continuing to review other generic semaglutide submissions, meaning more competition could enter the market in the future.
